Poolbeg Pharma plc (AIM: POLB, ‘Poolbeg Pharma’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that, further to

Poolbeg to present at Master Investor Show, BioTrinity & Participate in a Panel Discussion at LSX World Congress

Grant further strengthens Poolbeg’s global intellectual property (“IP”) portfolio

Termination of proposed combination with HOOKIPA Pharma Inc.

Combination of Poolbeg and HOOKIPA Pharma Inc. Offer Update – Extension to PUSU Deadline

Further to the announcement on 2 January 2025 (the “2.4 Announcement”) and the update on the potential combination of Poolbeg and HOOKIPA announced on 7 January 2025, the following amendment

Further to the announcement on 2 January 2025 (the “2.4 Announcement”), the Boards of Poolbeg and HOOKIPA are pleased to confirm that significant HOOKIPA shareholder, Gilead Sciences Inc. (“Gilead”), has

The boards of directors (each a “Board”) of HOOKIPA Pharma Inc. (“HOOKIPA”) and Poolbeg Pharma plc (“Poolbeg”) are pleased to announce that they have entered into non-binding discussions for an

Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

Further strengthens Poolbeg’s robust intellectual property portfolio.